UroGen Pharma
Mr. Nussbaum is a successful entrepreneur and executive with deep expertise in the business of the pharmaceutical industry. His work revolves around constant and active involvement in companies, providing them with strategic and business development oversight. He has served as a director for UroGen since May 2013.
Mr. Nussbaum is a Managing Partner and co-founder of Ponfiax Group, which has established seven funds with over one billion dollars under management and invested in over 100 portfolio companies around the globe. The group has established more than 19 startups since it was incorporated in 2005.
In the past, Mr. Nussbaum served on the board of directors for Kite Pharma (sold to Gilead) and cCEM Therapeutics (sold to Merck). He has also chaired Ocon Medical and NasVax Therapeutics and was CEO at Spearhead Ltd. and Biomedix Ltd.
Currently, Mr. Nussbaum also sits on the board of Eloxx (ELOX), ArQule (ARQL), Prevail (PRVL), and Lutris. He also serves as Keros Therapeutics’ Chairman of the Board.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
UroGen Pharma
UroGen Pharma is a biopharmaceutical company that builds novel solutions to revolutionize the way specialty cancers and urologic diseases are treated – because patients deserve better options.